SCHEMBL29965262

SCHEMBL29965262

CCOC(=O)CN1CC[C@@H](C(=O)OCC)C[C@H]1CC(C)C

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.44
▸ ALDH1A1 P00352 8/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ GAA P10253 2/20 0.37
▸ ATM Q13315 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ PKM P14618 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29965675 0.87 MAPT (0.46) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL23727122 0.80 MAPT (0.47) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL13398533 0.72 ALDH1A1 (0.47) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL28976959 0.71 ALDH1A1 (0.58) MAPTALDH1A1SMN1; SMN2GAAKDM4E
SCHEMBL587189 0.70 MAPT (0.34) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL581103 0.69 GAA (0.35) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL23467070 0.69 MAPT (0.50) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL8871550 0.69 KDM4E (0.54) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL23467066 0.69 MAPT (0.50) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL9367156 0.68 ALDH1A1 (0.38) ALDH1A1CYP2C19MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022204109-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NEWAVE PHARMACEUTICAL INC. (US) 2022-09-29 — — WO disclosed
Send feedback